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Abstract
Due to its strong immune stimulatory effects through TLR9, CpG-containing oligodeoxynucleotides (CpG ODN) have been
tested in multiple clinical trials as vaccine adjuvant for infectious diseases and cancer. However, immune suppression
induced by systemic administration of CpGs has been reported recently. In this study, we evaluated the impact of CpGs in
an acute rickettsiosis model. We found that systemic treatment with type B CpG (CpG-B), but not type A CpG (CpG-A), at 2
days after sublethal R. australis infection induced mouse death. Although wild-type (WT) B6 and IDO
2/2 mice showed
similar survival rates with three different doses of R. australis infection, treatment with CpG-B after sublethal infection
consistently induced higher mortality with greater tissue bacterial loads in WT but not IDO
2/2 mice. Also, CpG-B treatment
promoted the development of higher serum concentrations of proinflammatory cytokines/chemokines through IDO.
Furthermore, while T cell-mediated immune responses enhanced by CpG-B were independent of IDO, treatment with CpG-B
promoted T cell activation, PD-1 expression and cell apoptosis partially through IDO. A depletion study using anti-mPDCA-1
mAb indicated that plasmacytoid dendritic cells (pDC) were not required for CpG-B-induced death of R. australis-infected
mice. Additionally, the results in iNOS
2/2 mice suggested that nitric oxide (NO) was partially involved in CpG-B-induced
death of R. australis-infected mice. Surprisingly, pre-treatment with CpG-B before administration of a lethal dose of R.
australis provided effective immunity in WT, IDO
2/2 and iNOS
2/2 mice. Taken together, our study provides evidence that
CpGs exert complex immunological effects by both IDO-dependent and -independent mechanisms, and that systemic
treatment with CpGs before or after infection has a significant and distinct impact on disease outcomes.
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Introduction
TLR9 is expressed intracellularly in various cells including B
cells, monocytes, macrophages, NK cells, dendritic cells (DCs),
and plasmacytoid dendritic cells (pDCs). Activation of TLR9 by its
ligand, CpG ODN, induces a predominant Th1 innate and
adaptive immune response, including secretion of pro-inflamma-
tory cytokines, and IFN-inducible cytokines/chemokines, induc-
tion of IgG isotype switching and antibody secretion, differenti-
ation of Th1 cells, and enhancement of NK and CTL functional
activities [1,2]. Previous studies have extensively shown that
pretreatment with CpGs provides solid protection against various
infectious diseases [3,4,5,6] and immunotherapy for cancer and
allergy [7,8]. Currently, synthetic CpGs are being tested in
multiple clinical trials as adjuvants for vaccines against infectious
diseases and cancer [9,10].
As the first and rate-limiting enzyme in the catabolism of
tryptophan, indoleamine 2,3-dioxygenase (IDO) has been recently
documented to play an immunosuppressive role in peripheral
tolerance in pregnancy, infection, transplantation, autoimmunity,
allergy, and cancer [11,12]. A recent study of experimental asthma
has demonstrated that systemic treatment with CpGs induces
strong pulmonary IDO activity to inhibit Th-mediated lung
inflammation [13]. Further studies also showed that CpGs exert
an immune suppressive effect by induction of IDO. It has been
reported that systemic administration of CpGs to mice induces
rare CD19
+ DCs in spleen to express IDO and to acquire potent T
cell suppressor activity through costimulation of CTLA-4 and/or
PD-1 [14,15]. Similarly, compared to T cell activation induced by
subcutaneous administration of CpGs, systemic treatment with
CpGs suppresses T cell expansion and CTL activity via induction
of IDO [16]. Taken together, CpGs may exert either immune
stimulatory or suppressive functions, depending on the route of
application, such as subcutaneous versus intravenous or intraper-
itoneal administration.
In the present study, we further evaluated the immunological
effects of CpGs in a mouse model of an acute infectious disease,
rickettsiosis, which is an emerging/re-emerging infectious disease
caused by tick-borne pathogens of the genus Rickettsia [17,18,19].
We found that, although pre-treatment with CpG-B provided
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  Medical  Branchcomplete immunity against an ordinarily lethal dose of R. australis,
systemic treatment with CpG-B after a sublethal dose of R. australis
induced death of the animals. Our results indicate that IDO is
involved in CpG-B-mediated immune responses and the timing of
CpG treatment affects the infectious disease outcome.
Methods
Mice
C57BL/6J (B6), IDO
2/2 (IDO1-deficient) and iNOS
2/2 mice
on B6 background were purchased from the Jackson Laboratory
(Bar Harbor, ME). IDO
2/2 mice were bred and housed in the
University Animal Facility. Sex- and gender-matched, 8–12 wk
old mice were used in all studies. Experimental mice were housed
in a biosafety level 3 facility, and all experiments and procedures
were approved by the Institutional Animal Care and Use
Committee of the University of Texas Medical Branch, Galveston.
Rickettsial infection
Rickettsia australis (Cutlack strain) were passaged and maintained
in embryonated chicken yolk sacs in our laboratory [17]. The 10%
yolk sac suspension stock in SPG buffer (218 mM sucrose, 10 mM
potassium phosphate, pH 7.0, 5 mM potassium glutamate)
contained 4610
7 pfu per ml. After diluted in SPG buffer, the
indicated dose of R. australis (200 ml per mouse) was injected i.v.
through the tail vein. Control mice were inoculated with 200 mlo f
10% yolk sac in SPG buffer. Mice were monitored daily for signs
of illness until day 14.
CpG ODNs
Type B CpG (CpG-B, ODN 1826 sequence: 59-TCCAT-
GACGTTCCTGACGTT-39) and ODN 1826 control, Type A
CpG (CpG-A, ODN 1585 sequence: 59- GGGGTCAACGTT-
GAGGGGGG -39) and ODN 1585 control were purchased from
InvivoGen (San Diego, CA). For in vivo experiments, 50 mgo f
CpGs or CpG control per mouse were injected i.v. 2 days before
or after R. australis infection.
IDO enzymatic activity assay
Tissue IDO enzymatic activity was measured by a colorimetric
method with minor modifications [20]. Briefly, spleen, lung, liver
and brain tissues were collected from mice on day 5 post-infection
and homogenized. After centrifugation, the tissue lysates (150 ml)
were added into an equal amount of 26 IDO buffer (100 mM
PBS, pH 6.5, 40 mM ascorbate, 20 mM methylene blue, 200 mg/
ml catalase, and 800 mM L-tryptophan; all reagents were
purchased from Sigma-Aldrich (St. Louis, MO) and incubated
for 1 h at 37uC. The reaction was stopped with the addition of
50 ml of 30% trichloroacetic acid and further incubated for 30 min
at 52uC. After centrifugation, supernatant was mixed with an
equal amount of Ehrlich’s reagent (2% p-dimethylaminobenzalde-
hyde in acetic acid). The color was allowed to develop for 10 min,
and then the absorbance was measured at 490 nm in a
spectrophotometer. Kynurenine (Kyn) concentration in the
supernatant was calculated by an L-Kyn standard curve. The
IDO activity was expressed as nmol Kyn formed/h/mg protein.
The amount of protein in the samples was measured by bis-
cinchonic acid (BCA) method with bovine serum albumin as
standard.
Quantification of rickettsial loads by real-time PCR
To determine the rickettsial loads in infected organs, mouse
tissues including spleen, liver, lung and brain were collected on day
5 postinfection and homogenized. DNA was extracted using a
DNeasy tissue kit (Qiagen, Valencia, CA), and rickettsial loads
were determined using an iCycler IQ from Bio-Rad (Hercules,
CA). The following primers and probes (Biosearch Technologies,
Novato, CA) targeting R. australis citrate synthase (CS) gene
(U59718.1) and mouse glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) gene were used as described previously [21]: CS
forward primer 59-GAGAGAAAATTATATCCAAATGTT-
GAT-39, CS reverse primer 59-AGGGTCTTCGTG-
CATTTCTT-39, CS probe 59-FAM-CATTGTGCCATC-
CAGCCTACGGT-BHQ-1-39, GAPDH forward primer 59-
CAACTACATGGTCTACATGTTC-39, GAPDH reverse prim-
er 59-CTCGCTCCTGGAAGATG-39, and GAPDH probe 59-
FAM-CGGCACAGTCAAGGCCGAGAATGGGAAGC-BHQ-
1-39. The results of bacterial loads were normalized using GAPDH
data for the same sample and expressed as the number of CS
copies per 10
6 copies of GAPDH.
Flow cytometry
The following mAbs were purchased from BD Biosciences (San
Jose, CA) or eBiosciences (San Diego, CA): fluorescein isothiocy-
anate (FITC)-conjugated anti-CD8 (53-6.7), anti-Ly-6C (AL-21),
anti-IFN-c (XMG1.2); phycoerythrin (PE)-conjugated anti-CD19
(1D3), anti-Ly-6G (1A8), anti-IL-10 (JES5-16E3), anti-TNF-a
(MP6-XT22), anti-IL-17A (TC11-18H10), anti-PD-1 (J43); PerCP
Cy5.5-conjugated anti-CD3 (145-2C11); PE-Cy7 anti-CD4 (RM4-
5); allophycocyanin (APC)-conjugated anti-CD25 (PC61), anti-
CD11b (M1/70), anti-CD8 (53-6.7); as well as isotype control Abs,
including FITC-conjugated rat IgG1, PE-conjugated rat IgG1,
IgG2b, and APC-conjugated rat IgG2a. PE-conjugated anti-
mouse/rat Foxp3 (FJK-16s) staining reagents were purchased
from eBiosciences.
At day 5 post-infection, spleens from individual mice were
collected and processed. After red blood cells were lysed, single
splenocytes were counted and stained for surface markers.
Intracellular Foxp3 staining was performed following the manu-
facturer’s protocol. For intracellular cytokine staining, splenocytes
were restimulated with phorbol 12-myristate 13-acetate (PMA)/
Ionomycin/GolgiStop (BD Biosciences) for 5 h. After T cell
surface marker staining, intracellular cytokines (IFN-c, IL-10,
TNF-a, IL-17) were stained with antibodies by following
cytofixation/permeabilization with a Cytofix/Cytoperm Kit
(BD Biosciences). Samples were evaluated on a FACSCanto
or LSRFortessa flow cytometer (BD Biosciences), and results
were analyzed by using FlowJo software (TreeStar, Ashland, OR,
USA).
Measurement of serum cytokines by Bio-Plex
Sera were collected from mice at day 5 post-infection. Multiple
serum cytokines and chemokines (IL-1b, IL-6, IL-10, IL-12p40,
IFN-c, TNF-a, MCP-1, and RANTES) were measured by Bio-
Plex cytokine assay (Bio-Rad Laboratories, Hercules, CA). Serum
IFN-c levels were verified by Quantikine ELISA kit (R&D
Systems, Minneapolis, MN).
Tissue histology and TUNEL assay
On day 5 post-infection, liver and spleen tissues were collected,
fixed with 10% neutral buffered formalin, and embedded in
paraffin. Tissue sections (5 mm thickness) were stained with
hematoxylin and eosin. TUNEL assay was performed on
formalin-fixed, paraffin-embedded liver and spleen tissues by
using in situ cell death detection kit (fluorescein) according to
the manufacturer’s instructions (Roche Diagnostics, Indianapolis,
IN).
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Functional grade of anti-mouse PDCA-1 (JF05-1C2.4.1) and
PE-conjugated anti-mPDCA-1 mAbs were purchased from
Miltenyi Biotec (Auburn, CA). To deplete plasmacytoid dendritic
cells (pDCs) in vivo, C57BL/6J mice were injected i.v. with 500 mg
of anti-mPDCA-1 mAb or control rat IgG one day before R.
australis infection, then four times i.p. with 250 mg of mAb or rat
IgG at one hour before, and 2, 4, 6 days after i.v. infection with
5610
5 pfu of R. australis. Then, 50 mg of CpG-B per mouse were
injected i.v. on day 2 post-infection. Survival of mice was
monitored for 14 days. At day 7, splenocytes from control and
pDC-depleted mice were stained with FITC-conjugated anti-Ly-
6C and PE-conjugated anti-mPDCA-1. The efficiency of pDC
depletion was 80–90%.
Statistical analyses
Numeric data were presented as means 6 standard deviation.
Statistical analyses for survival curves were calculated by the log-
rank test, and the comparison between two different groups was
determined by a two-tailed Mann-Whitney test using GraphPad
Prism, version 5.00, for Windows (GraphPad Software, San Diego,
CA). Statistically significant values are referred to as follows: *,
p,0.05; **, p,0.01.
Results
Systemic treatment with CpG-B, but not CpG-A, after
sublethal R. australis infection induced death of mice
By using the synthesized CpG ODNs, we investigated the
immunological effects of a TLR9 agonist on rickettsial infection.
As demonstrated in our previous study [17], infection with R.
australis induced disease in C57BL/6J mice. All mice survived
5610
5 pfu, all died after infection with 2610
6 pfu, and half
survived infection with 1610
6 pfu (Figure 1A). Interestingly, we
found that, systemic treatment with CpG-B (50 mg of CpG-B per
mouse, i.v.) at 2 days after sublethal R. australis infection (5610
5
pfu/mouse) induced mortality in mice (Figure 1B). Mice infected
with a lethal dose of R. australis (2610
6 pfu/mouse) died very
similarly with or without post-infection treatment with CpG-B
(data not shown). In contrast to predominant induction of type I
IFNs by CpG-A, CpG-B is known to induce strong NF-kB
signaling and B cell activation but only weak type I IFN secretion
[1]. We confirmed that treatment with CpG-B, but not CpG-A, at
2 days after sublethal R. australis infection induced death of mice
(Figure 1C). This result suggests that activation of NF-kB signaling
by CpG-B rather than induction of type I IFN by CpG-A causes
death of R. australis-infected mice.
CpG-B induced death of R. australis-infected mice
through IDO
Previous studies have reported that systemic treatment with
CpGs induces strong IDO expression in tissues [13,16]. We
wished to determine whether the IDO pathway is involved in
CpG-induced death in R. australis-infected mice. By using IDO
2/2
mice, we initially found that WT and IDO
2/2 mice had
comparable survival rates at three different doses of R. australis
infection (Figure 2A), although R. australis infection did induce
strong tissue expression of IDO in WT mice (Figure 2D). These
results suggested a minor role of IDO in R. australis infection.
However, we found that, when 50 mg of CpG-B per mouse was
injected i.v. into WT and IDO
2/2 mice 2 days after sublethal R.
australis infection, 80–90% of IDO
2/2 mice survived compared to
the high mortality in WT mice (Figure 2B). At day 5 post-infection,
treatment with CpG-B resulted in significantly increased tissue
bacterial loads in infected WT and IDO
2/2 mice compared to
controls. However, tissue bacterial loads were significantly higher
in CpG-B-treated, R. australis-infected WT mice than those in
CpG-B-treated, R. australis-infected IDO
2/2 mice (Figure 2C). We
also confirmed that CpG alone and R. australis infection with or
without CpG-B treatment induced strong IDO enzymatic activity
in WT mouse tissues (especially in the lung) but not in IDO
2/2
mouse tissues (Figure 2D). Tryptophan 2,3-dioxygenase (TDO) is
constitutively expressed in liver, and the assay for IDO enzymatic
activity does not distinguish IDO and TDO from one another in
this organ. These results indicate that IDO plays a critical role in
CpG-B-induced mouse death in rickettsial infection.
CpG-B promoted different profiles of serum
proinflammatory cytokines/chemokines
Using the Bio-Plex assay, we measured the levels of multiple
proinflammatory cytokines/chemokines in mouse sera at day 5
post-infection. We found that treatment with CpG-B significantly
enhanced the production of IFN-c, IL-10, IL-1b, IL-6, and
RANTES in R. australis-infected WT mice, compared to the only
slightly enhanced production of IL-10, IL-1b, IL-6, TNF-a, and
RANTES in CpG-B-treated, R. australis-infected IDO
2/2 mice
(Figure 3). Clearly, the serum levels of multiple cytokines (IFN-c,
IL-10, IL-1b, and IL-6) in CpG-B-treated, R. australis-infected WT
mice were significantly higher than those in CpG-B-treated, R.
australis-infected IDO
2/2 mice (Figure 3). Interestingly, infection
with R. australis induced little production of IL-12p40 and IL-17
(data not shown) in vivo. These results indicate that CpG-B
differentially promotes the production of serum proinflammatory
cytokines/chemokines during rickettsial infection.
T cell-mediated immune response enhanced by CpG-B in
R. australis-infected mice is IDO-independent
To analyze T cell-mediated immune responses, spleen cells at day
5 post-infection were collected and restimulated with PMA/
Ionomycin/GolgiStop ex vivo.W ef o u n dt h a t ,R. australis infection
induced comparable intracellular cytokine production in CD4
+ T
cells from WT and IDO
2/2 mice. Treatment with CpG-B
significantly increased cytokine production, especially IFN-c and
TNF-a,i nC D 4
+ T cells from both WT and IDO
2/2, R. australis-
infected mice compared to the controls (Figure 4). While CpG-B
significantly increased IFN-c production in CD8
+ Tc e l l so fi n f e c t e d
WT mice, treatment with CpG-B did not affect IFN-c production in
CD8
+T cellsfrom infected IDO
2/2mice(Figure4).Taken together,
these results indicate that treatment with CpG-B enhanced some T
cell-mediated immune responses in an IDO-independent manner.
CpG-B promoted T cell activation and PD-1 expression
rather than increasing Treg cells during R. australis
infection
As systemic treatment with CpGs has been reported to induce
splenic Treg activation through IDO-expressing CD19
+ DCs
[14,15], we investigated regulatory T cells in spleen by staining
with anti-CD25 and anti-Foxp3 Abs. Based on forward and side
scatter (FSC and SSC) parameters, we observed that rickettsial
infection induced two different cell populations which could be
gated as R1 (quiescent cell populations, dominantly present in the
control group) and R2 (activated cell populations, mainly present
in the rickettsiae-infected groups) (Figure 5A). These two cell
populations were associated with splenomegaly in R. australis-
infected mice with or without CpG-B treatment in contrast to the
normal spleen size in control mice. In R1 cells (quiescent cell
CpG-B Induced Mouse Death in Rickettsial Infection
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e34062populations), a 2-fold increase in the frequency of Treg cells (CD4
+
CD25
+ Foxp3
+) was observed in R. australis-infected mice, and
CpG-B treatment did not affect the frequency of Treg cells in
infected WT and IDO
2/2 mice, although CpG-B alone slightly
increased the frequency of Treg cells compared to controls (Figure
5A). Interestingly, in R2 cells (activated cell populations), we
observed that while rickettsial infection decreased the frequencies
of Treg cells in the infected mice, rickettsial infection clearly
induced T cell activation (CD4
+ and/or CD8
+ CD25
+ Foxp3
2)
(Figure 5A). Furthermore, treatment of infected mice with CpG-B
significantly enhanced the percentages of activated T cells partially
through IDO (Figure 5B). These results suggest that treatment
with CpG-B does not affect the frequency of Treg cells but mainly
promotes T cell activation during rickettsial infection.
Furthermore, we determined that, in the R1 and R2 cell
populations, rickettsial infection induced greater PD-1 expression
Figure 1. CpG-B, not CpG-A, treatment induces mortality in otherwise sublethal rickettsial infection. B6 mice (8 mice per group) were
injected i.v. with different doses of R. australis (Ra) (A). At day 2 after infection with 5610
5 pfu of R. australis,5 0mg of ODN control (ODN 1826 control)
and CpG-B (ODN 1826) per mouse were injected i.v., respectively (B). At day 2 after B6 mice (8 mice per group) were injected i.v. with R. australis
(6610
5 pfu), 50 mg of ODN control (ODN 1585 control), CpG-A (ODN 1585), and CpG-B (ODN 1826) per mouse were injected i.v., respectively (C).
Survival was monitored for 14 days.
doi:10.1371/journal.pone.0034062.g001
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+ and CD8
+ T cells compared to that of the control group
(Figure 6). Interestingly, treatment with CpG-B dramatically
increased PD-1 expression both on CD4
+ and CD8
+ T cells
especially in the R2 population (activated cells) in R. australis-
infected WT mice. To some extent, treatment with CpG-B only
promoted PD-1 expression on R2- but not R1-T cells in R.
australis-infected IDO
2/2 mice (Figure 6). Therefore, treatment
with CpG-B promoted PD-1 expression on quiescent and/or
activated T cells partially via IDO.
CpG-B induced cell apoptosis in R. australis-infected mice
through IDO
The above determinations of increased T cell activation and
PD-1 expression on T cells after CpG-B treatment led us to
investigate whether this T cell over-activation is related to cell
death. In addition, the IDO pathway has been reported to be
involved in the regulation of T cell apoptosis [22,23]. We then
performed in situ TUNEL assay on spleen and liver tissues from
control and R. australis-infected mice. Histopathology revealed
cellular infiltrations in R. australis-infected mouse liver, but there
was no difference in these infiltrates between R. australis-infected
mice with or without CpG-B treatment (Figure S1A). Similar
observations were found in lung and brain tissues (data not shown).
While TUNEL assay clearly showed that infection with R. australis
induced apoptosis in mouse spleen cells, greater quantities of
apoptotic cells were observed in spleen from CpG-B-treated, R.
australis-infected WT mice than infected IDO
2/2 mice (Figure 7).
Most of the apoptotic cells were observed in the periarteriolar
Figure 2. CpG-B induced death of R. australis-infected mice through IDO. WT and IDO
2/2 mice (6–8 mice per group) were injected i.v. with
different doses of R. australis. Mouse survival was monitored for 14 days (A). 50 mg of ODN control (ODN 1826 control) or CpG-B (ODN 1826) per
mouse were injected i.v. into B6 and IDO
2/2 mice (8 mice per group) at day 2 after infection with 5610
5 pfu of R. australis, respectively. Mouse
survival was monitored for 14 days (B). Tissue bacterial loads determined by realtime PCR (C) and tissue IDO enzymatic activity determined by
modified colorimetric assay (4 mice per group) were measured on day 5 post-infection (D). The representative results are shown as mean 6 SD from
three independent experiments. * p,0.05.
doi:10.1371/journal.pone.0034062.g002
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apoptotic cells observed in liver of R. australis-infected mice (Figure
S1B). These results suggest that CpG-B promotes tissue cell
apoptosis during rickettsial infection via an IDO-dependent
mechanism.
CpG-B-induced death of R. australis-infected mice is pDC-
independent
To determine whether CpG-B-induced mouse death in
rickettsial infection is mediated by induction of IDO-expressing
pDCs, we performed pDC depletion by using functional grade
anti-mPDCA1 antibody in vivo. The efficiency of pDC depletion
was 80%–90% on day 7 (data not shown). Depletion of pDC did
not prevent the death of R. australis-infected mice treated with
CpG-B (Figure 8). This result strongly suggests that CpG-B-
induced death of R. australis-infected mice is independent of
pDC.
Nitric oxide is partially involved in CpG-B-induced death
of R. australis-infected mice
Since nitric oxide (NO) has been reported to play a critical role
in antirickettsial activity and in CpG-mediated protection against
Listeria monocytogenes [24,25,26], we further examined the role of
NO in rickettsial infection in mice. Infection of WT and iNOS
2/2
mice with a sublethal dose or a 1 LD50 dose of R. australis caused
no major differences in mortality between WT and iNOS
2/2 mice
(Figure 9A). This result suggests that iNOS plays a dispensable role
in R. australis infection in vivo. However, treatment with CpG-B at 2
days after R. australis infection in iNOS
2/2 mice resulted in
delayed mouse deaths compared to WT mice (Figure 9B),
suggesting that NO is partially involved in CpG-B-induced death
of R. australis-infected mice.
Pre-treatment with CpG-B protected against lethal
infection with R. australis
CpGs have been used as a vaccine adjuvant in numerous
infectious disease models [1]. Clearly, pretreatment with CpG-B at
2 days before infection efficiently protected mice against an
ordinarily lethal dose of R. australis not only in WT mice, but also
in IDO
2/2 and iNOS
2/2 mice (Figure 10A and 10B). Therefore,
pre-treatment with CpG-B offers strong and protective immunity.
Discussion
Our previous studies had demonstrated that CD8
+ T cells and
IFN-c play critical roles in protection against rickettsial infection
[18,19]. In addition, TLR4-mediated innate immune responses
also contribute to disease control [27]. We embarked upon
determining whether use of an immunopotentiator such as CpG
could enhance Th1-like immunity to increase immune resistance
against lethal rickettsial infection. Indeed, pre-treatment with
CpG-B before an ordinarily lethal challenge provided strong
protection, which is consistent with previous findings in other
infectious diseases. However, systemic treatment with CpG-B after
sublethal rickettsial infection induced mouse death. The mecha-
nistic studies suggested that the CpG-B-induced mouse death after
an ordinarily sublethal infection was probably due to IDO-
mediated immune regulation of the cytokine profile and T cell
over-activation and apoptosis.
Activation of TLR9 leads to both proinflammatory cytokine
production through a NF-kB-dependent pathway and type I IFN
production through an IFN regulatory factor 7 (IRF7)-dependent
pathway [28,29]. The bifurcated signaling via TLR9 can be
induced by different classes of CpGs [1]. We found that treatment
with CpG-B, but not CpG-A, induced mouse death after an
Figure 3. IDO is involved in the production of CpG-B-mediated-proinflammatory cytokines/chemokines. At day 2 after infection with
5610
5 pfu of R. australis,5 0mg of ODN control (ODN 1826 control) and CpG-B (ODN 1826) per mouse were injected i.v. into WT and IDO
2/2 mice (4
mice per group). Mouse sera (6–8 mice per group) were collected at day 5 post-infection, multiple cytokines/chemokines were measured by Bio-plex
assay and serum IFN-c levels were verified by ELISA. * p,0.05 and ** p,0.01.
doi:10.1371/journal.pone.0034062.g003
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+ and CD8
+ T cells. At day 2 after infection with 5610
5 pfu of R. australis,5 0mg
of ODN control (ODN 1826 control) and CpG-B (ODN 1826) per mouse were injected i.v. into WT and IDO
2/2 mice (4 mice per group). At day 5 post-
infection, spleen cells (1610
6/ml) from individual mice were restimulated with PMA/Ionomycin/GolgiStop for 5 h. Multiple intracellular cytokines as
indicated were measured in CD4
+ and CD8
+ T cells. The percentages of intracellular cytokine production in gated T cells were shown as mean 6 SD in
the corner (A). Representative statistical data are shown from one of three independent experiments. * p,0.05 (B).
doi:10.1371/journal.pone.0034062.g004
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PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e34062Figure 5. CpG-B treatment promotes T cell activation partially through IDO, without altering the frequencyof Treg cells. At day 5
post-infection, spleen cells from individual mice (4 mice per group) were stained with the indicated cell surface markers and then for intracellular
Foxp3. Based on forward scatter (FSC) and side scatter (SSC) parameters, two populations were defined as quiescent cells (region 1, R1) and activated
cells (region 2, R2) (A). The percentages of CD25
+ Foxp3
+ Treg cells and CD25
+ Foxp3
2 activated T cells gated in CD3
+ CD4
+ and CD3
+ CD8
+ T cells
from R1 and R2 populations are shown as mean 6 SD in the corner. Representative statistical data are shown from one of three independent
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doi:10.1371/journal.pone.0034062.g005
Figure 6. Treatment with CpG-B enhanced PD-1 expression on T cells partially through IDO. The percentages of PD-1 on CD4
+ and CD8
+
T cells that were gated on R1 and R2 CD3
+ T cells (as in Figure 5) were determined by FACS at day 5 post-infection (A). The percentages of PD-1
expression in gated CD4
+ and CD8
+ T cells are shown as mean 6 SD (B). Representative statistical data are shown from one of three independent
experiments. * p,0.05.
doi:10.1371/journal.pone.0034062.g006
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systemic treatment with CpG-B in R. australis-infected mice
enhanced the production of multiple serum cytokines/chemokines
and T cell-mediated immune responses (Figure 3 and 4).
Furthermore, depletion of pDC did not affect the lethal outcome
of R. australis-infected mice when treated with CpG-B (Figure 8).
These results indicate that CpG-B-induced proinflammatory
cytokines, rather than type I IFNs (from pDCs), are the major
contributing factors for death in R. australis-infected mice.
Additional studies using mice deficient in the type I IFN signaling
(e.g., IFNAR
2/2 or IRF7
2/2 mice) would verify and strengthen
this conclusion.
Recent studies have identified an important role of IDO in
mediating immunosuppressive effects of CpGs in the steady state
[14,16]. IDO can suppress T cell responses directly through
tryptophan starvation and metabolite-mediated apoptosis [22,23],
or indirectly via induction of Treg cells by IDO-expressing pDC
[14,15,30]. Our results showed that, although the IDO pathway is
dispensable in rickettsial infection, IDO played an important role
in CpG-B-induced mouse death in ordinarily sublethal R. australis
infection since treatment with CpG-B induced very low mortality
in IDO
2/2 mice (Figure 2B). Although treatment with CpG-B
alone increased the frequency of CD4
+ CD25
+ Foxp3
+ Treg cells
compared to controls, treatment with CpG-B did not alter the
frequencies of Treg cells in R. australis-infected WT or IDO
2/2
mice due to infection itself (Figure 5). However, we observed that
CD4
+ and CD8
+ T cells from CpG-B-treated, R. australis-infected
WT but not IDO
2/2 mice expressed very high levels of CD25 and
PD-1, which correlated with the occurrence of apoptosis in the
spleen (Figures 5, 6, 7). Thus, our results indicate that in a
rickettsial infection IDO may not be involved in induction of Treg
cells by CpG-B. Instead, IDO may be involved in regulation of
CpG-induced T cell activation and apoptosis through its
metabolites and/or the PD-1/PD-L1 pathway [22,23,30]. Al-
though determining whether Treg activity was altered by CpG-B
via IDO during rickettsial infection requires further investigation,
the T cell-mediated immune response enhanced by CpG-B is
independent of IDO indicating no involvement of Treg cells
(Figure 4). Furthermore, in vivo Treg cell depletion studies by our
laboratory [31] and others suggest that Treg-mediated immune
suppression may play a minor role in acute systemic infectious
diseases [32,33].
Although the immune suppressive role of IDO has been
generally accepted, increasing amounts of data suggest that IDO
serves more than one function in the immune system [34,35].
Inhibition of IDO activity in the K/BxN murine rheumatoid
Figure 7. Treatment with CpG-B induced cell apoptosis
through IDO. Apoptotic cells in spleen tissues at day 5 postinfection
were detected by TUNEL assay (magnification 620). Green (fluorescein)
staining of apoptotic cells and blue (DAPI) staining of nuclei. Shown are
the representative results from three independent experiments.
doi:10.1371/journal.pone.0034062.g007
Figure 8. CpG-B-induced death of R. australis-infected mice is independent of pDC. Depletion of pDC was performed as in Methods. At day
2 after infection with R. australis (5610
5 pfu), 50 mg of CpG-B per mouse were injected i.v. into control or pDC-depleted mice. Mouse survival (6–8
mice per group) was monitored for 14 days.
doi:10.1371/journal.pone.0034062.g008
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of the arthritic symptoms with decreased autoantibody titers,
reduced levels of inflammatory cytokines, and an attenuated
disease course [36]. Specifically, IDO
2/2 mice and IDO inhibitor
(1-methyl-tryptophan)-treated mice have decreased production of
proinflammatory cytokines and increased survival from endotoxin
shock [37], and IDO activity in bacteremic patients correlates with
disease severity and case fatality [38]. Our results in this study that
during rickettsial infection CpG-B differentially promoted proin-
flammatory cytokine production and T cell over-activation
through IDO suggest a constituent role of IDO in CpG-B
signaling. Thus, our study provides additional evidence that IDO
may play a more complex role than its immunosuppressive role
under certain disease conditions [39].
Furthermore, systemic treatment with CpGs causes lethal toxic
shock within 18 h in LPS- or D-galactosamine-sensitized mice due
to TNF-a-mediated fulminant apoptosis of liver cells [40,41]. In
this study, mice treated with CpG-B at day 2 post-infection began
dying on day 6. Also, we did not observe massive apoptosis of
hepatocytes. Nevertheless, CpG-B treatment did promote cytokine
production during rickettsial infection (Figure 3), reminiscent of
the systemic inflammatory response syndrome. Thus, synergistic
induction of proinflammatory cytokines (such as through NF-kB
activation [42]) and/or regulation of the immune response by
CpGs during rickettsial infection could be responsible for the lethal
outcome in mice. In addition, a recent study discovered that
administration of TLR2 ligand exacerbates bacterial sepsis
through neutrophil depletion by apoptosis [43]. However, we
found no evidence for bone marrow neutrophil exhaustion in this
study, since rickettsial infection induced similar neutrophilia in
blood and bone marrow with or without CpG-B treatment, and
CpG-B only slightly increased cellular recruitment of neutrophils
and monocytes in the spleen (data not shown).
In contrast to previous findings of in vitro NO-mediated
antirickettsial activity [24,25], we found that deficiency of iNOS
in iNOS
2/2 mice did not affect rickettsial infection (Figure 9A).
Further investigation is needed to determine if another NOS
isoform, such as eNOS from endothelial cells (the main target cells
for rickettsiae), plays an anti-rickettsial role in vivo. In addition, we
determined that iNOS is partially involved in CpG-B-induced
death of R. australis-infected mice (Figure 9B). Our results suggest
that NO is also involved in the CpG-B signaling pathway probably
through NF-kB activation [44]. On the other hand, pre-treatment
with CpG-B clearly provides protection against lethal rickettsial
infection in WT, IDO
2/2 and iNOS
2/2 mice (Figure 10),
indicating that CpG-B-induced immunostimulation provided
strong protection against subsequent infection by an IDO- and
iNOS-independent mechanism.
CpGs have proven to be highly effective activators of innate and
adaptive immunity, with applications in the prevention and
treatment of infectious diseases, allergic conditions and cancer.
However, post-exposure therapy with TLR9 activation is generally
Figure 9. NO is partially involved in CpG-B-induced death of R. australis-infected mice. WT and iNOS
2/2 mice (8 mice per group) were
injected i.v. with different doses of R. australis (A). At day 2 after infection with 5610
5 pfu of R. australis,5 0mg of ODN control (ODN 1826 control) and
CpG-B (ODN 1826) per mouse were injected i.v. into WT and iNOS
2/2 mice (8 mice per group), respectively (B). Mouse survival was monitored for 14
days.
doi:10.1371/journal.pone.0034062.g009
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with certain chronic infectious diseases [45,46]. Our study
highlighted the adverse effects of CpG-B when administrated
post-infectioninanacuteinfectiousdiseasemodel.Anotherfactorto
be considered for immunotherapy is the route of administration,
since systemic (i.v. or i.p.) application of CpGs results in T cell
suppression whereas local subcutaneous (s.c.) administration
induces immune stimulation [16]. A recent study has also provided
evidence that i.v. and s.c. CpG administration were far less effective
than peritumoral administration in cancer immunotherapy [47].
In conclusion, our study suggests that CpG exerts its
immunological effects through both IDO-dependent and -
independent mechanisms. Our findings for the complex and
paradoxical roles for CpGs during infection have significant
clinical implications. This study calls for a cautious use of CpG in
immunomodulation in certain situations.
Supporting Information
Figure S1 Histopathologic analysis and apoptotic cell
death of R. australis infected liver. Control and infected
liver of mice at day 5 post-infection (H & E staining, magnification
620) (A). Apoptosis characterized by TUNEL assay in control and
infected mice at day 5 post-infection (magnification 620). Green
(fluorescein) staining of apoptotic cells and blue (DAPI) staining of
nuclei. Shown are the representative results from three indepen-
dent experiments (B).
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